Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CARM
- Price
- 0.44
- Stock movement down
- -0.06 (-12.18%)
- Company name
- Carisma Therapeutics Inc.
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 18.43M
- Ent value
- 44.74M
- Price/Sales
- 0.91
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -57.17%
- 3 year return
- -67.08%
- 5 year return
- -50.62%
- 10 year return
- -38.50%
Last updated: 2025-08-27
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CARM does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.91 |
| Price to Book | - |
| EV to Sales | 2.21 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 41.79M |
| EPS (TTM) | -1.54 |
| FCF per share (TTM) | -1.89 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 20.27M |
| Gross profit (TTM) | 14.03M |
| Operating income (TTM) | -66.77M |
| Net income (TTM) | -63.80M |
| EPS (TTM) | -1.54 |
| EPS (1y forward) | -0.52 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 69.23% |
| Operating margin (TTM) | -329.46% |
| Profit margin (TTM) | -314.78% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 26.88M |
| Net receivables | 0.00 |
| Total current assets | 34.14M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 7.71M |
| Total assets | 42.06M |
| Accounts payable | 1.73M |
| Short/Current long term debt | 3.32M |
| Total current liabilities | 10.56M |
| Total liabilities | 53.18M |
| Shareholder's equity | -11.13M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -83.35M |
| Capital expenditures (TTM) | 696.00K |
| Free cash flow (TTM) | -78.41M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -151.70% |
| Return on Invested Capital | 736.21% |
| Cash Return on Invested Capital | 904.82% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.48 |
| Daily high | 0.56 |
| Daily low | 0.43 |
| Daily Volume | 3.90M |
| All-time high | 347.40 |
| 1y analyst estimate | 1.00 |
| Beta | 3.71 |
| EPS (TTM) | -1.54 |
| Dividend per share | - |
| Ex-div date | 8 Mar 2023 |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| CARM | S&P500 | |
| Current price drop from All-time high | -99.87% | -3.04% |
| Highest price drop | -99.95% | -56.47% |
| Date of highest drop | 16 May 2025 | 9 Mar 2009 |
| Avg drop from high | -85.83% | -11.04% |
| Avg time to new high | 220 days | 12 days |
| Max time to new high | 2846 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
18.43M
Marketcap category
Small-cap
Description
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidate includes CT-2401, which is in preclinical trail for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Employees
46
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page